Verastem, Inc.
LSE: 0LOV.L0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- London Stock Exchange
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- CEO
- Daniel W. Paterson
- Employees
- 78
- Headquarters
- Needham, United States
- IPO year
- 2018
- Market cap
- $345.5M
- Website
- https://www.verastem.com
Loading 0LOV…
Loading profile data…Frequently asked questions about 0LOV
What does Verastem, Inc. (0LOV.L) do?
Verastem, Inc., a development-stage biopharmaceutical company, focusing on developing and commercializing drugs for the treatment of cancer. Its product in development includes VS-6766, a dual rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) clamp that blocks MEK kinase activity and the ability of RAF to phosphorylat...
Where does 0LOV.L trade?
Verastem, Inc. (0LOV.L) trades on the London Stock Exchange.
What sector is 0LOV.L in?
Verastem, Inc. (0LOV.L) operates in the Healthcare sector, specifically in the Medical - Pharmaceuticals industry.
Who is the CEO of Verastem, Inc.?
Daniel W. Paterson is the chief executive officer of Verastem, Inc. (0LOV.L).
Where is Verastem, Inc. headquartered?
Verastem, Inc. is headquartered in United States.
Does 0LOV.L pay a dividend?
Verastem, Inc. (0LOV.L) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 0LOV.L go public?
Verastem, Inc. (0LOV.L) completed its initial public offering in 2018.